Methods and systems for treatment based on tissue fluid volume

GB2645525APending Publication Date: 2026-11-11BBI MEDICAL INNOVATIONS LLC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
GB2026006518
Authority / Receiving Office
GB · GB
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-08
Filing Date
2023-09-14
Publication Date
2026-11-11

AI Technical Summary

Technical Problem

Current methods for detecting pressure ulcers rely on subjective visual skin assessments, which are limited by sensitivity to skin tone and do not detect damage until it is visible on the skin surface, leading to delayed interventions.

Method used

The use of sub-epidermal moisture (SEM) measurements to detect localized edema by taking multiple readings at different locations on the body, calculating an SEM delta, and determining if the fluid volume is greater at specific locations based on predetermined thresholds.

Benefits of technology

This method allows for the early detection of pressure-induced tissue damage before visible manifestations occur, enabling timely and appropriate interventions to prevent further damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides methods and systems for measuring an increase in the volume of fluid in tissue, for treating a patient in need of treatment for increased volume of fluid in tissue, for
Need to check novelty before this filing date? Find Prior Art

Description

METHODS AND SYSTEMS FOR TREATMENT BASED ON TISSUE FLUID VOLUMECROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 581,524, filed September 8, 2023, which is incorporated by reference in its entirety herein.BACKGROUND OF THE INVENTION|0002] Pressure ulcers (PUs) represent one of the leading unsolved medical complications worldwide. In the United States, PUs affect 2.5 million patients and costing more than twenty billion dollars annually. PUs increase the length of hospital stay, decrease quality of life and account for up to 60,000 deaths in the US annually. The impact of a PU increases as the severity of the injury increases, making it crucial to detect damage early and put appropriate care in place to reverse the damage.

[0003] Detecting PUs currently relies on subjective tissue assessment such as a visual skin assessment (VS A), whereby characteristics such as skin redness and non-blanchable erythema are identified by a care provider. However, relying on visual skin changes means that objective and anatomy-specific preventive care typically does not begin until damage has already occurred and visibly manifests on the skin surface. VS A is further limited by its sensitivity to skin tone, with damage in darker skin being detected later, resulting in delayed interventions. Thus, there is an unmet need for methods that can detect pressure-induced tissue damage prior to visible and tactile manifestations on the skin surface.SUMMARY

[0004] The subject matter of the present disclosure is based on the findings that sub- epidermal moisture (SEM) measurements can measure the volume of fluid in a tissue. The subject matter of the present disclosure is also based on the findings that SEM measurements can detect localized edema in skin.

[0005] In an aspect, the present disclosure provides a method of treating an increase in fluid content in tissue in a patient in need thereof, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the firstlocation and the second location; (d) determining in the patient in need thereof that the volume of fluid is greater at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold; and (e) administering a treatment for localized edema. In an aspect, the two or more SEM readings taken at the first location are spaced no more than 4 cm apart. In an aspect, the first location and the second location are spaced no less than 10 cm apart. In an aspect, the predetermined threshold is 0.6. [0006| In an aspect, the present disclosure provides a method of determining the relative volume of fluid in tissue, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (d) determining that the relative volume of fluid is at least 1 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6. In an aspect, the method further comprises the step of determining that the volume of fluid is at least 2ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.9. In an aspect, the two or more SEM readings taken at the first location are spaced no more than 4 cm apart. In an aspect, the first location and the second location are spaced no less than 10 cm apart. In an aspect, the predetermined threshold is 0.6.[0007 J In an aspect, the present disclosure provides a method of measuring an increase in the volume of fluid in tissue, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (d) determining that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold. In an aspect, the two or more SEM readings taken at the first location are spaced no more than 4 cm apart. In an aspect, the first location and the second location are spaced no less than 10 cm apart. In an aspect, the predetermined threshold is 0.6.[0008[ In an aspect, the present disclosure provides a method of determining the efficacy of a treatment at a first location of the body with localized edema, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at the first location on the body with localized edema; (b) taking two or more SEM readings at a second location on the body,wherein the second location of the body does not have localized edema; (c) calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (d) administering the treatment;(e) taking two or more SEM readings at the first location post-treatment; (f) taking two or more SEM readings at the second location post-treatment; (g) calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location post-treatment and the second location post-treatment; (h) determining that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and (i) determining that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold. In an aspect, the two or more SEM readings taken at the first location are spaced no more than 4 cm apart. In an aspect, the first location and the second location are spaced no less than 10 cm apart. In an aspect, the treatment is systemic. In an aspect, the treatment is localized. In an aspect, the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low-friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress.

[0009] In an aspect, the present disclosure provides a method of adjusting a treatment for localized edema, the steps comprising: (a) administering a level-N treatment for localized edema; (b) taking two or more subepidermal moisture (SEM) readings at a first location on the body with localized edema; (c) taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema; (d) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (e) continuing to administer the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold; (f) administering a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold; and (g) administering a level-(N- 1) treatment if the SEM delta is lesser than the second pre-determined threshold. In anaspect, the two or more SEM readings taken at the first location are spaced no more than 4 cm apart. In an aspect, the first location and the second location are spaced no less than 10 cm apart. In an aspect, the treatment is systemic. In an aspect, the treatment is localized. In an aspect, the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low-friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress.[0010| In an aspect, the present disclosure provides a system for use in treating increase in fluid content in tissue in a patient in need thereof, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient's body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; and (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (ii) determining in the patient in need thereof that the SEM delta is greater than or equal to a predetermined threshold; (iii) determining in the patient in need thereof that the fluid content is greater at the location where the highest SEM reading is taken; and (iv) providing a notification that the patient is in need of treatment.[0011 [ In an aspect, the present disclosure provides a system for measuring an increase in localized edema, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; and (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (ii) providing a signal that the volume of fluid is increased at the location where the highest SEM reading istaken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.[0012[ In an aspect, the present disclosure provides a system for determining the efficacy of a treatment at a first location of the body with localized edema, comprising: (a) an SEM scanner configured to (i) take two or more SEM readings at a first location and a second location on the patient’s body prior to treatment, and to (ii) take two or more SEM readings at the first location and the second location on the patient’s body post-treatment; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner (i) the four or more SEM readings at the first location and the second location prior to treatment, and (ii) the four or more SEM readings at the first location and the second location post-treatment; and (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location prior to treatment; (ii) calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location post-treatment; (iii) providing a signal that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and (iv) providing a signal that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.|0013] In an aspect, the present disclosure provides a system for adjusting the level of treatment in a patient receiving a level-N treatment for localized edema, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (ii) providing a signal to a caregiver to continue administering the level-N treatment if the SEM delta is between a first pre-determined threshold and a second predetermined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold; (iii) providing a signal to a caregiver to administer a level-(N+l)treatment if the SEM delta is greater than the first pre-determined threshold; and (iv) providing a signal to a caregiver to administer a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Aspects of the disclosure are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by w ay of example and are for purposes of illustrative discussion of aspects of the disclosure. In this regard, the description and the drawings, considered alone and together, make apparent to those skilled in the art how aspects of the disclosure may be practiced.

[0015] FIG. 1 illustrates some exemplary steps of pressure ulcer formation.[0016 FIG. 2A depicts an exemplary experimental setup for measuring the fluid content in skin.

[0017] FIG. 2B depicts how fluid is injected into the heel bone prominence of a pig’s hock.

[0018] FIG. 3 depicts the visualization of edema formation using dyed test fluid.

[0019] FIG. 4A shows the changes in SEM measurements at an injection site and a control site for ten porcine specimens with ten repeated measurements for each point.

[0020] FIG. 4B shows the SEM delta in SEM measurements between the control site and the injection site at each volume of fluid injected.|0021] FIG. 5 depicts the change in SEM measurements up to 4 cm away from the injection site.

[0022] FIG. 6 shows the change in SEM delta measurements as the fluid volume in the skin is increased.DETAILED DESCRIPTION[0023 [ The present disclosure describes methods and systems for measuring an increase in the volume of fluid in tissue, for treating a patient in need of treatment for increased volume of fluid in tissue, for determining the efficacy of such treatment, and for adjusting the treatment.

[0024] This description is not intended to be a detailed catalog of all the different ways in which the disclosure may be implemented, or all the features that may be added to the instant disclosure. For example, features illustrated with respect to one embodiment may be incorporated into other embodiment, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the disclosure contemplates that in some embodiments of the disclosure, any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant disclosure. In other instances, well-known structures, interfaces, and processes have not been shown in detail in order not to unnecessarily obscure the invention. It is intended that no part of this specification be construed to effect a disavowal of any part of the full scope of the invention. Hence, the following descriptions are intended to illustrate some particular embodiments of the disclosure, and not to exhaustively specify all permutations, combinations and variations thereof.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description of the disclosure herein is for the purpose of describing particular aspects or embodiments only and is not intended to be limiting of the disclosure.|0026] All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and / or paragraph in which the reference is presented. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques that would be apparent to one of skill in the art.

[0027] Unless the context indicates otherwise, it is specifically intended that the various features of the disclosure described herein can be used in any combination. Moreover, the present disclosure also contemplates that in some embodiments of the disclosure, any feature or combination of features set forth herein can be excluded or omitted.[0028| The methods disclosed herein include and comprise one or more steps or actions for achieving the described method. The method steps and / or actions may be interchanged with one another without departing from the scope of the present disclosure. In other words, unlessa specific order of steps or actions is required for proper operation of the embodiment, the order and / or use of specific steps and / or actions may be modified without departing from the scope of the present disclosure.[00291 As used in the description of the disclosure and the appended claims, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.[0030) As used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).[0031) The terms “about” and “approximately” as used herein when referring to a measurable value such as a length, a frequency, or a measurement value and the like, is meant to encompass variations of ± 20%, ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1% of the specified amount.[00321 As used herein, phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y. As used herein, phrases such as “between about X and Y” mean “between about X and about Y” and phrases such as “from about X to Y” mean “from about X to about Y.”[0033) As used herein, the term "exemplary" is used to mean serving as an example, instance, or illustration. Any embodiment or aspect described as “exemplary ” is not necessarily to be construed as preferred or advantageous over other embodiments or aspects, nor is it meant to preclude equivalent structures and techniques known to those of ordinary skill in the art. Rather, use of the word exemplary’ is intended to present concepts in a concrete fashion, and the disclosed subject matter is not limited by such examples.

[0034] As used herein, the term “sub-epidermal moisture” or “SEM” refers to the increase in tissue fluid and localized edema caused by vascular leakiness and other changes that modify the underlying structure of the damaged tissue in the presence of continued pressure on tissue, apoptosis, necrosis, and the inflammatory process. SEM may include intracellular and extracellular fluid. Without being bound by theory’, when skin tissue is damaged, inflammation at the site of injury can cause blood vessels to dilate and increase blood flow into the skin tissue. There can also be an increase in blood vessel permeability, allowing fluid, proteins, and white blood cells to migrate from the circulation to the site of skin tissue damage. The flood of fluids, cells, and other substances to the injured site produces swelling and redness, and increases the amount of SEM m the damaged skin tissue.

[0035] As used herein, “localized edema” refers to swelling due to an excessive accumulation of fluid at a specific anatomic site. Localized edema may or may not be clinically apparent by visual inspection. As opposed to localized edema, peripheral edema does not become clinically apparent by visual inspection until the interstitial volume has increased by 2.5 to 3 liters because the tissues constituting the interstitium can easily accommodate several liters of fluid.

[0036] The SEM in tissue may be measured by one or more of any techniques known to those of ordinary skill in the art. In an aspect. SEM in a tissue is measured by impedance, capacitance, resistance, or inductance of the tissue. In an aspect, SEM in a tissue is measured by capacitance of the tissue. SEM may also be measured by evaluating the interaction of incident electromagnetic radiation with the tissue. In an aspect, SEM is measured by absorption of electromagnetic radiation incident on the tissue. In an aspect, SEM is measured by reflectance of electromagnetic radiation incident on the tissue. In an aspect, SEM is measured by transmission of electromagnetic radiation incident on the tissue. In an aspect, SEM is measured by scattering of electromagnetic radiation incident on the tissue. In an aspect, the electromagnetic radiation incident on the tissue is visible light. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 350 nm to about 800 nm. In an aspect, the electromagnetic radiation incident on the tissue is ultraviolet light. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 150 nm to about 400 nm. In an aspect, the electromagnetic radiation incident on the tissue is infrared light. In an aspect, the electromagnetic radiation incident on the tissue is near infrared light. In an aspect, the electromagnetic radiation incident on the tissue is mid infrared light. In an aspect, the electromagnetic radiation incident on the tissue is far infrared light. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 800 nm to about 2500 nm. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 1000 nm to about 1350 nm. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 1350 nm to about 1500 nm. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 1500 nm to about 2100 nm. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 2.5 pm to about 25 pm. In an aspect, the electromagnetic radiation incident on the tissue has a wavelength of about 25 pm to about 1 mm.

[0037] In an aspect, SEM is measured by more than one technique known to those of ordinary skill in the art. In an aspect, SEM is measured by at least one of absorption,reflectance, transmission, or scattering of electromagnetic radiation incident on the tissue. In an aspect, SEM is measured by evaluating the interaction of incident electromagnetic radiation with the tissue, wherein the electromagnetic radiation comprises more than one spectral band. In an aspect, SEM is measured by evaluating the interaction of incident electromagnetic radiation with the tissue, wherein the electromagnetic radiation comprises more than one spectral band. In an aspect, a spectral band has a wavelength of about 1000 nm to about 1350 nm. In an aspect, a spectral band has a wavelength of about 1350 nm to about 1500 nm. In an aspect, a spectral band has a wavelength of about 1500 nm to about 2100 nm. [0038| As used herein, “tissue biocapacitance7’ refers to a biophysical marker for detecting tissue damage based on the increased level of fluids that build up in the interstitial space. Without being bound by theory, the level of biocapacitance in a tissue is correlated to the fluid content in a tissue. In an aspect, SEM is measured by biocapacitance. In an aspect, the methods described herein comprise a step of measuring the biocapacitance in a tissue. In an aspect, the methods described herein comprise a step of measuring the biocapacitance of the skin. In an aspect, the biocapacitance measured with the methods described herein vary linearly with the SEM in the tissue. In an aspect, the biocapacitance measured with the methods described herein van' non-linearly with the SEM in the tissue.[0039} U.S. Patent Application Serial No. 14 / 827,375 (“the’375 application”) discloses an apparatus that measures the sub-epidermal capacitance using a bipolar sensor, where the sub- epidermal capacitance corresponds to the moisture content of the target region of skin of a patient. The‘375 application also discloses an array of these bipolar sensors of various sizes. [0040J U.S. Patent Application Serial No. 15 / 134, 110 discloses an apparatus for measuring sub-epidermal moisture (SEM) similar to the device shown in Figure 3.[0041 } Both U.S. Patent Application Serial Nos. 14 / 827,375 and 15 / 134,110 are incorporated herein by reference in their entireties. How ever, the SEM values of the present disclosure may be measured by any similar or equivalent devices or techniques that would be apparent to one of skill in the art. For example, a device measuring the SEM values of the present disclosure may be a wired device, a wireless device, or a system comprising various components in communication with each other.[0042} In an aspect, SEM is measured by a SEM measuring device. In an aspect. SEM is measured by an SEM scanner. In an aspect, SEM is measured by the Provizio™ SEM scanner.[0043} As used herein, a “patient” may be a human or animal subj ect.

[0044] As used herein, “treatment of a disease” means the management and care of a patient having developed the disease, condition or disorder. The purpose of treatment is to combat the disease, condition or disorder. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.

[0045] As used herein, “extracellular fluid” or “ECF” refers to bodily fluid contained outside of cells, including plasma, interstitial fluid, and transcellular fluid.

[0046] As used herein, “delta” or “SEM delta” refers to a calculated difference between two SEM measurements or SEM values. In an aspect, an SEM delta is the difference between the highest and the lowest SEM reading from a plurality of SEM readings. In an aspect, an SEM delta is the difference between the highest and the lowest SEM reading from a plurality of SEM readings taken from a plurality of locations. In an aspect, an SEM delta is the difference between the highest SEM reading and the average SEM reading from a plurality of SEM readings. In an aspect, an SEM delta is the difference between the average SEM reading from a plurality of SEM readings and the lowest SEM reading. In an aspect, an SEM delta is the difference between the average SEM reading from the first location and the average SEM reading from the second location. In an aspect, an SEM delta is the difference between a first average SEM reading from a first plurality' of SEM readings and a second average SEM reading from a second plurality of SEM readings.|0047] FIG. 1 depicts some exemplary' steps in the formation of a pressure ulcer. Without being bound by theory, the triggering point is the deformation-caused death of the first group of cells. Due to the inflammatory process, the permeability of the nearby vascular walls is increased to facilitate the migration of immune cells to the site of inflammation. Consequentially, a localized increase in interstitial tissue fluid content occurs. This increased volume of interstitial fluid may amplify the interstitial pressure at the anatomy, which may be exacerbated by the presence of a bony prominence at the periphery that further confines the environment. Bony prominences are the areas of bone that are close to the skin's surface. Examples of bony prominences include, but are not limited to, the sacrum, ischia, trochanters, shoulder blades, tailbone, heels, knees, and elbows. The amplified pressure increases the cell death rate and accelerates the tissue-damage pathway, with a snowballing effect that if perpetuated, can degenerate into deeper and extended tissue loss.[0048| The present disclosure provides, and includes, methods for measuring the relative volume of fluid in tissue. The present disclosure also provides methods for measuring anincrease in the volume of fluid in tissue. In an aspect, the method comprises taking two or more SEM readings at a first location on the body. In an aspect, the method comprises taking two or more SEM readings at a second location on the body. In an aspect, two or more SEM measurements may be obtained at each location. In an aspect, at least one, at least two. at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 SEM measurements are taken at each location.

[0049] In an aspect, a location on the body is an area or volume of skin tissue SEM readings may be taken. In an aspect, a location on the body is an anatomical site, e.g., a sternum, a sacrum, a heel, a scapula, an elbow, an ear, and other fleshy tissues of a patient. In an aspect, a location has an area that is the area in contact with an SEM measurement device. In an aspect, a location is a point in the center of an area in contact with an SEM measurement device. In an aspect, a second location is bisymmetric relative to the first location. In an aspect, the first and second locations are bisymmetric with respect to a patient’s body. As used herein, “bisymmetric” refers to a pair of locations that are approximately equidistant from a line of symmetry. For example, the left thumb and the right thumb are bisymmetric locations on a patient’s body relative to the centerline (e.g., spine).[00501 In an aspect, a first location is spatially distinct from a second location. In an aspect, a first location and a second location are spaced at least 1 cm apart, at least 2 cm apart, at least 3 cm apart, at least 4 cm apart, at least 5 cm apart, at least 6 cm apart, at least 7 cm apart, at least 8 cm apart, at least 9 cm apart, or at least 10 cm apart. In an aspect, a first location and a second location are spaced no more than 1 cm apart, no more than 2 cm apart, no more than 3 cm apart, no more than 4 cm apart, no more than 5 cm apart, no more than 6 cm apart, no more than 7 cm apart, no more than 8 cm apart, no more than 9 cm apart, or no more than 10 cm apart. In an aspect, a first location and a second location are spaced no less than 1 cm apart, no less than 2 cm apart, no less than 3 cm apart, no less than 4 cm apart, no less than 5 cm apart, no less than 6 cm apart, no less than 7 cm apart, no less than 8 cm apart, no less than 9 cm apart, or no less than 10 cm apart.

[0051] In an aspect, the method comprises calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location. In one aspect, an SEM delta between two SEM readings from a plurality of SEM readings is determined. In an aspect, the SEM delta between the highest and the lowest SEM readings from a plurality of SEM readings is determined. In an aspect, the SEMdelta between the highest SEM reading and the average SEM reading from a plurality of SEM readings is determined. In an aspect, the SEM delta between the average SEM reading from a plurality of SEM readings and the lowest SEM reading is determined. In an aspect, the SEM delta between the average SEM reading from the first location and the average SEM reading from the second location is determined. In an aspect, the SEM delta between a first average SEM reading from a first plurality' of SEM readings and a second average SEM reading from a second plurality' of SEM readings is determined.

[0052] In an aspect, the method comprises determining that the volume of fluid is increased at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold. In an aspect, SEM measurements measure the volume of fluid in a tissue at the measurement location. In an aspect, SEM readings correlate with the volume of fluid in a tissue at the measurement location. In an aspect, a higher SEM reading represents a higher volume of fluid in a tissue at the measurement location. In an aspect, an increase in SEM reading represents an increase in the volume of fluid in a tissue at the measurement location. In an aspect, a lower SEM reading represents a higher volume of fluid in a tissue at the measurement location. In an aspect, a decrease in SEM reading represents an increase in the volume of fluid in a tissue at the measurement location. In an aspect, the volume of fluid is greater at the location where the highest SEM reading is taken. In an aspect, the volume of fluid is lesser at the location where the highest SEM reading is taken. In an aspect, the volume of fluid is greater at the location where the lowest SEM reading is taken. In an aspect, the volume of fluid is lesser at the location where the lowest SEM reading is taken.

[0053] In an aspect, the method comprises determining that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold. In an aspect, the predetermined threshold is about 0. 1, about 0.2. about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0.

[0054] In an aspect, the method comprises determining that the relative volume of fluid is greater at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold. In an aspect, the method comprises determining that the relative volume of fluid is at least 1 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.1, greater than 0.2, greater than 0.3,greater than 0.4, greater than 0.5, greater than 0.6, greater than 0.7, greater than 0.8, greater than 0.9, greater than 1.0, greater than 1.1, greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5, greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, or greater than 2.0. In an aspect, the method comprises determining that the relative volume of fluid is at least 1 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6. In an aspect, the method comprises determining that the relative volume of fluid is at least 2 ml greater at the location wi th the highest SEM reading if the SEM delta is greater than 0.5, greater than 0.6, greater than 0.7, greater than 0.8, greater than 0.9, greater than 1.0, greater than 1.1, greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5, greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, or greater than 2.0. In an aspect, the method comprises determining that the relative volume of fluid is at least 3 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6, greater than 0.7, greater than 0.8. greater than 0.9, greater than 1.0, greater than 1.1. greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5, greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, or greater than 2.0. In an aspect, the method comprises determining that the relative volume of fluid is at least 4 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6, greater than 0.7, greater than 0.8, greater than 0.9, greater than 1.0, greater than 1.1, greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5, greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, or greater than 2.0.|0055] The present disclosure provides, and includes, a method of treating an increase in fluid content in tissue in a patient in need thereof. In an aspect, the method comprises taking two or more SEM readings at a first location on the body. In an aspect, the method comprises taking two or more SEM readings at a second location on the body. In an aspect, the method comprises calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location. In an aspect, the method comprises determining in the patient in need thereof that the volume of fluid is greater at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold. In an aspect, the method comprises administering a treatment for localized edema.[0056| In an aspect, a patient is in need of treatment for an increase in fluid content in tissue when the SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location is greater than or equal to apredetermined threshold. In an aspect, a patient is in need of treatment when the SEM delta is greater than 0.2, greater than 0.3, greater than 0.4, greater than 0.5, greater than 0.6, greater than 0.7, greater than 0.8, greater than 0.9, greater than 1.0, greater than 1.1, greater than 1.2, greater than 1.3, greater than 1.4, greater than 1.5. greater than 1.6, greater than 1.7, greater than 1.8, greater than 1.9, or greater than 2.0. In an aspect, a patient is in need of treatment when the SEM delta is equal to about 0.2, equal to about 0.3, equal to about 0.4, equal to about 0.5, equal to about 0.6, equal to about 0.7, equal to about 0.8, equal to about 0.9, equal to about 1.0, equal to about 1.1, equal to about 1.2, equal to about 1.3, equal to about 1.4, equal to about 1.5, equal to about 1.6, equal to about 1.7, equal to about 1.8, equal to about 1.9, or equal to about 2.0. In an aspect, a patient is in need of treatment when the SEM delta is in the range of about 0. 1 to about 1.7. In an aspect, a patient is in need of treatment when the SEM delta is in the range of about 0.2 to about 1.6. In an aspect, a patient is in need of treatment when the SEM delta is in the range of about 0.5 to about 1.6. In an aspect, a patient is in need of treatment when the SEM delta is in the range of about 0.6 to about 1.6. In an aspect, the predetermined threshold is about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6. about 1.7, about 1.8. about 1.9, or about 2.0.[0057} In an aspect, the treatment is providing good nutrition. In an aspect, the treatment is providing a standard mattress. In an aspect, the treatment is turning the patient at regular intervals. In an aspect, the treatment is providing a heel boot. In an aspect, the treatment is changing the support surface. In an aspect, the treatment is applying dressing to the patient’s skin. In an aspect, the treatment is changing the sheet cover to a low-friction sheet over. In an aspect, the treatment is providing a low-friction padded mattress surface. In an aspect, the treatment is turning the patient at shorter intervals. In an aspect, the treatment is applying a barrier cream to the patient’s skin. In an aspect, the treatment is applying neuromuscular stimulation. In an aspect, the treatment is applying topical cream to enhance perfusion. In an aspect, the treatment is providing a silicone pad. In an aspect, the treatment is repositioning the patient with a wedge. In an aspect, the treatment is changing to a dynamic mattress. In an aspect, the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular interv als, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low-friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applyingneuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress. In an aspect, the treatment is systemic. In an aspect, the treatment is localized.[00581 The present disclosure provides, and includes, a method of determining the efficacy of a treatment at a first location of the body with localized edema. In an aspect, the method comprises taking two or more subepidermal moisture (SEM) readings at a first location on the body with localized edema. In an aspect, the method comprises taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema. In an aspect, the method comprises calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location. In an aspect, the method comprises administering the treatment for localized edema. In an aspect, the method comprises taking two or more SEM readings at the first location post-treatment. In an aspect, the method comprises taking two or more SEM readings at the second location post-treatment. In an aspect, the method comprises calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location post-treatment and the second location post-treatment. In an aspect, the method comprises determining that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold. In an aspect, the method comprises determining that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.

[0059] In an aspect, a treatment is efficacious if the SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location decreases after treatment. In an aspect, the predetermined efficacy threshold is about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 1.0. In an aspect, the treatment is efficacious if the second SEM delta is lower than the first SEM delta by at least 0. 1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, or at least 1.0. In an aspect, the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by at least 0.1, at least 0.2, at least 0.3. at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8. at least 0.9, or at least 1.0.[0060| The present disclosure provides, and includes, a method of adjusting a treatment for localized edema. In an aspect, the method comprises administering a level-N treatment forlocalized edema. In an aspect, the method comprises taking two or more subepidermal moisture (SEM) readings at a first location on the body with localized edema. In an aspect, the method comprises taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema. In an aspect, the method comprises calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location. In an aspect, the method comprises continuing to administer the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold. In an aspect, the method comprises administering a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold. In an aspect, the method comprises administering a level-(N-l) treatment if the SEM delta is lesser than the second predetermined threshold.

[0061] In an aspect, N is an integer. In an aspect, N is equal to or greater than 1. In an aspect, a level-N treatment is more effective than a level-0 treatment. In an aspect, a level-(N+l) treatment is more effective than a level-N treatment. In an aspect, a level-(N-l) treatment is less effective than a level-N treatment. In an aspect, a level-(N+l) treatment is a more aggressive treatment than a level-N treatment. In an aspect, a level-(N-l) treatment is a less aggressive treatment than a level-N treatment. In an aspect, a level-(N+l) treatment is a more intensive treatment than a level-N treatment. In an aspect, a level-(N-l) treatment is a less intensive treatment than a level-N treatment.

[0062] In an aspect, the first predetermined threshold is about 0.1, about 0.2. about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0. In an aspect, the second predetermined threshold is about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7. about 0.8, about 0.9. about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0. In an aspect, the first threshold is 0.5 and the second threshold is 0.1. In an aspect, the first threshold is 0.6 and the second threshold is 0.2.

[0063] The present disclosure also provides systems that implement the methods disclosed herein.

[0064] The present disclosure provides, and includes, a system for use in treating increases in fluid content in tissue in a patient in need thereof. In an aspect, the system comprises anSEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body. In an aspect, the system comprises a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location. In an aspect, the system comprises a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, performs the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location, (ii) determining in the patient in need thereof that the SEM delta is greater than or equal to a predetermined threshold, (iii) determining in the patient in need thereof that the fluid content is greater at the location where the highest SEM reading is taken, and (iv) providing a notification that the patient is in need of treatment.

[0065] In an aspect, an SEM scanner is a biocapacitance measurement device. In an aspect, an SEM scanner is the Provizio™ SEM scanner. In an aspect, an SEM scanner is the Provizio™ SEM scanner with a Gateway Dashboard.[0066| In an aspect, the system implements the methods described herein by way of a machine, with executable code stored on an electronic storage location of the system, such as, for example, on the memory or electronic storage unit. In an aspect, the processor is a single core or multi core processor, or a plurality of processors for parallel processing. In an aspect, the machine-executable instructions are computer code. In an aspect, the machine-executable instructions are stored on memory. In an aspect, the machine-executable instructions are transmitted to the system. In an aspect, the system includes memory (e.g., random-access memory, read-only memory, flash memory), an electronic storage unit (e.g., hard disk), a communication interface (e.g., network adapter) for communicating with one or more other systems, and peripheral devices, such as cache, other memory, data storage or electronic display adapters. In an aspect, the system can communicate with one or more remote computer systems through a network. In an aspect, the netw ork can be the Internet, an internet or extranet, or an intranet or extranet that is in communication with the Internet. In an aspect, the network is a telecommunication or data netw ork. In an aspect, the network is one or more computer servers, which can enable distributed computing, such as cloud computing. In an aspect, the network can implement a peer-to-peer network with the aid of a computer system, which may enable devices coupled to the computer system to behave as a client or a server. In an aspect, the system can communicate w ith a remote computer system of a user(e.g., medical professional, or subject). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. In an aspect, a user can access the system 1101 via a network. In an aspect, the system can include a user interface, for example, for user to input information. In an aspect, the system includes a graphical user interface. In an aspect, the system includes a web-based user interface. In an aspect, the system includes an output unit. In an aspect, the system includes an electronic display.[0067| In an aspect, the system provides a notification that the patient is in need of treatment. In an aspect, the notification is a graphical alert on an electronic device. In an aspect, the notification is an audio alert. In an aspect, the notification is an alarm.[00681 The present disclosure provides, and includes, a system for measuring an increase in localized edema. In an aspect, the system comprises an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patienf s body. In an aspect, the system comprises a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location. In an aspect, the system comprises a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, performs the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location, and (ii) providing a signal that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.[0069| In an aspect, the system provides a signal that the volume of fluid is increased. In an aspect, the signal is a graphical alert on an electronic device. In an aspect, the signal is an audio alert. In an aspect, the signal is an alarm.|OO70] The present disclosure provides, and includes, a system for determining the efficacy of a treatment at a first location of the body with localized edema. In an aspect, the system comprises an SEM scanner configured to (i) take two or more SEM readings at a first location and a second location on the patient’s body prior to treatment, and to (ii) take two or more SEM readings at the first location and the second location on the patient’s body posttreatment. In an aspect, the system comprises a processor electronically coupled to the SEMscanner, the processor configured to receive from the SEM scanner (i) the four or more SEM readings at the first location and the second location prior to treatment, and (ii) the four or more SEM readings at the first location and the second location post-treatment. In an aspect, the system comprises a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location prior to treatment; (ii) calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location post-treatment; (iii) providing a signal that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and (iv) providing a signal that the treatment is not efficacious if the second SEM delta is not low er than the first SEM delta by a predetermined efficacy threshold.

[0071] The present disclosure provides, and includes, a system for adjusting the level of treatment in a patient receiving a level-N treatment for localized edema. In an aspect, the system comprises an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body. In an aspect, the system comprises a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location. In an aspect, the system comprises a non-transitory' computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (ii) providing a signal to a caregiver to continue administering the level-N treatment if the SEM delta is between a first pre-determined threshold and a second predetermined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold; (iii) providing a signal to a caregiver to administer a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold; and (iv) providing a signal to a caregiver to administer a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.EXAMPLES

[0072] The present disclosure is illustrated by the following examples. The examples set out herein illustrate several aspects of the present disclosure but should not be construed as limiting the scope of the present disclosure in any manner.EXAMPLE 1 : Porcine model

[0073] Porcine skin has a similar structure and composition to human skin and is widely used in wound healing, inj ury and PU research (Kong R, Bhargava R. Characterization of porcine skin as a model for human skin studies using infrared spectroscopic imaging. Analyst, 136(11):2359-66 (2011); Seaton M, Hocking A, Gibran NS. Porcine Models of Cutaneous Wound Healing. ILAR Journal, 56(l):127-38 (2015); Yeung CC, Holmes DF, Thomason HA, Stephenson C, Derby B, Hardman MJ. An ex vivo porcine skin model to evaluate pressure-reducing devices of different mechanical properties used for pressure ulcer prevention. Wound Repair Regen. 24(6): 1089-96 (2016)).

[0074] The calcaneus of the porcine hindlimb provides a bony prominence similar in anatomical shape and subdermal tissue characteristics to many locations prone to ulceration on the human body, particularly the human heel. The porcine hind limbs are chosen as an appropriate model to mimic key aspects of the human soft tissue, while also being able to precisely control sub-epidermal moisture levels.

[0075] Porcine specimens (British Landrace breed) may be sourced from a processing facility7, such as Doyle Catering Meats, Dublin, Ireland. The specimens are refrigerated at 4°C immediately after slaughter, and are transported to the laboratory at 4°C within six hours of slaughter. Experiments are performed on the same day as the slaughter. Ten individual specimens are used for this study. Porcine specimens are collected from animals slaughtered in accordance with European export standards.[0076| The porcine specimen is positioned to provide a consistent angle at the heel articulation. The skin surface is washed with several consecutive steps of 70% ethanol / H2O and 100% ethanol solutions to remove any contaminants, and is dried by dabbing with paper towels prior to sampling. The sites of injections are selected to represent bony prominences with the highest probability7of developing pressure induced tissue damage in at-risk patients, as show n in FIG. 3.EXAMPLE 2: Induction of localized edema (subepidermal moisture)

[0077] Without being bound by theory, localized edema, or SEM, is characterized by a buildup of interstitial fluid at the site of injury and is a result of inflammation and the consequent enhanced interstitial pressure (Moore Z, Patton D. Rhodes SL, O'Connor T. Subepidermal moisture (SEM) and bioimpedance: a literature review of a novel method for early detection of pressure-induced tissue damage (pressure ulcers). Int Wound J., 14(2):331 -7 (2017)). To model a localized edema, precise volumes (1 ml to 4 ml) of fluid is delivered to ex vivo porcine soft tissues.

[0078] Briefly, localized edema within the tissue is introduced by intradermal injection of Dulbecco's Phosphate Buffered Saline (PBS) solution (Sigma- Aldrich, United States). While water alone has previously been used to test the device in physical models, pure water would alter the osmolarity of the tissue fluid (Peko Cohen L, Gefen A. Phantom testing of the sensitivity and precision of a sub-epidermal moisture scanner. Int Wound J , 16(4):979- 88(2019)). For this reason. PBS is used to match the osmolarity of the interstitial fluid.

[0079] A hypodermic needle (27G 0.4 x 14 mm, B. Braun Melsungen AG, Germany), is used to deliver PBS solution into the model. After visual inspection to avoid the presence of any air bubbles, the needle is inserted firmly for % of its length (10 mm) at an angle of approximately 30° to the skin surface, as shown in FIG. 2B. This procedure is used to establish an injection depth of approximately 3 mm from the skin surface (between 2.8 and 4.6 mm), which is within the established depth of penetration of the scanner sensor of ~3.6 mm (Ross G, Gefen A. Assessment of sub-epidermal moisture by direct measurement of tissue biocapacitance. Med Eng Phys. 73:92-9(2019)). The needle is not moved once it has been inserted into the model. The needle is secured in position for the duration of the experiment. As shown in FIG. 2A, the test fluid is delivered at 500 pl / min flow rate for a fixed volume of injection of 1000 pl PBS with a fluidic pump (Legato™ 110, single syringe infusion / withdraw pump, KDScientific) and a plastic syringe (BD Syringe with Luer Lock lOmL, Sigma- Aldrich).

[0080] It is confirmed by visual inspection that no fluid escaped from around the needle, and that the liquid is instead directed into the tissue at depths ranging between 2.8 mm and 4.6 mm to ensure that the edematous condition represented SEM changes at the dermis. Visible swelling is not apparent at 1 ml and becomes more obvious with 2 ml of fluid delivered.EXAMPLE 3: Validation of edema model - Colored dve tests

[0081] Regions next to the injection site are observed to also be swollen after the injection. As such, a colored dye is introduced to the test fluid to quantify the extent of localized edema formation (FIG. 3). In these tests, a solution of 1 : 10 blue dye / H2O (Blue Food Colour, The Pantry) is injected in increments of 1 ml from 0 ml to 4 ml in order to provide visual recognition of the edema formation. As shown in FIG. 3, the injection site is photographed, the area with color change is outlined and its surface area is quantified.

[0082] The fluid is observed to be dissipated within the tissue and that the extent of dissipation depends on the volume of fluid injected. With 1 ml of fluid delivered, a region of approximately 5 cm2around the injection site contains visible test fluid with no apparent visible swelling. With incremental injections, visible swelling is clear with the colored region grow ing to a maximum of 15 cm2with 4 ml of test fluid delivered. These results indicate that in a region of tissue, a localized increase in tissue fluid content is induced. Quantify ing the extent of fluid dissipation will enable selection of a control site within the anatomy but away from the site of injection, for subsequent SEM validation experiments.EXAMPLE 4: Measurement of SEM

[0083] To determine whether an SEM device can detect changes in sub-epidennal moisture, SEM readings are taken from the injection site (on the bony prominence) and at a control site at least 4 cm away from the site of injection (near the bony prominence; FIG. 3 left-most panel).10084] Briefly. SEM measurements are acquired using the Provizio® SEM Scanner (Bruin Biometrics LLC. Los Angeles, California). This device has a biocapacitance sensor; a coplanar capacitor made of two concentric electrodes. The device assesses changes in the biocapacitance of the tissue area in direct contact with the sensor surface. A single trained operator perfonns all scans for the whole duration of the data acquisition to eliminate interoperator error. The device expresses the readings in SEM values between 1.0 and 4.5 (arbitrary7units). In clinical use, after a minimum of three consecutive SEM readings, the device displays a SEM delta. This SEM delta value is the SEM delta between the minimum and the maximum SEM value registered within a predefined set of scans. In adults at risk of developing PUs, an elevated SEM delta (>0.6) indicates early-stage PU development and an increased risk of developing broken skin PUs and deep tissue injuries at the specific anatomical location (Bruin Biometrics Provizio® SEM Scanner User Manual. (2020); Gershon S, Okonkwo H. Evaluating the sensitivity, specificity' and clinical utility' ofalgorithms of spatial variation in sub-epidermal moisture (SEM) for the diagnosis of deep and early-stage pressure-induced tissue damage. J Wound Care. 30(l):41-53(2021)).[0085| It is observed that in all 10 specimens, SEM readings increased at the intervention site as moisture content increased (FIG. 4A). In all specimens, the relative rate of increase in SEM value to injected fluid volume is observed to reach a plateau at injections > 3 ml, indicating a biocapacitive threshold that is breached when the maximum dielectric constant for tissue fluid is reached at large volumes. Combining the data from all specimens, a statistically significant difference of 0.734 [95% CI 0.612, 0.886] in SEM values between control and injection sites (corresponding to a SEM delta) after 1ml injection (p=0.0052) is observed. As shown in FIG. 4B, this difference in SEM values increases to 1.0 [95%CI 0.807, 1.18] after 2 ml injection (p<0.001), 1.14 [95%CI 0.967, 1.3] after 3 ml injection (p<0.001), and 1.16 [95%CI 0.955, 1.33] after 4 ml injection (p<0.001; FIG. 4B). The area surrounding the intervention site also exhibits SEM changes, albeit at smaller magnitudes, leading to further investigations of the spatial sensitivity of the device around the edema’s proximity (Example 5).EXAMPLE 5: Identification of control sites and spatial sensitivity of SEM measurements [0086} To investigate the spatial sensitivity of SEM assessment technology, SEM data from sites at increasing distances from the intervention point (FIG. 5) is measured. In these tests, test fluid is delivered in 1 ml increments up to 4 ml, as before. Scans are then taken at the injection site and at locations 1 cm, 2 cm, 3 cm, and 4 cm away from the injection site. Such experiments not only measure the spatial sensitivity of the device, but also identify the minimum distance a control site should be to prevent the edema from affecting control regions.[0087} Briefly, the measuring points (Landmarks 0 to 4) are placed at an increased distance of 1 cm from each other along a straight line starting from the center of the edema (FIG. 3. panel 4). Four injections of 1 ml are performed following the same guidelines as for the data collected in Figure 4 on a specimens subset (N=l) in Examples 2, 3, and 4. For each injection, the SEM values are collected at all five locations, counting landmark 0 as the intervention site, for a total of 100 SEM readings. As a consequence of the edema development, SEM values are observed to increase at the injection site (consistent with Examples 2-4). At scans performed away from the injection site, a drop-off in sensitivity of SEM to fluid volume is observed, with a linear regression slope of 1.16 at 1 cm, 0.6 at 2 cm, -0.54 at 3 cm and -0. 18 at 4 cm (FIG. 5). The slope of the linear regression at 4 cm is not statistically significantly different from zero (p=0.21), indicating that there is no effect of fluid injection on SEM readings at this location. These results indicate that a suitable location for control measurements is at a distance of at least 4 cm from an injection site.EXAMPLE 6: SEM delta values correlate with increased localized moisture content [0088| The ability of the device to detect localized SEM is assessed by taking SEM readings at an injection site and a control site in a total of ten different porcine specimens.|0089] Briefly, for each specimen, two landmarks (an injection site and a control site) are established and a controlled edema is developed at the injection site (bony prominence) through four consecutive injections of 1 ml. Fluid is injected always at the bony prominence of the specimen. The readings are taken consistently in comparison with the control site, located 10 cm away from the injection site. Two SEM readings are taken at each landmark for every7single volume evaluation. The difference between the four SEM values is recorded as the SEM delta. The site of injection and the control site are marked to preserve consistency during the whole data acquisition process (see Figure 3).

[0090] The readings are repeated ten times for each consecutive 1 ml injection including the baseline (0 ml) resulting in a total of 500 SEM delta data points across 10 specimens. Variations in observed SEM delta values are attributed to changes in the tissue properties of individual specimens, as a consequence of an expected inter-specimen variability. As shown in FIG. 6, SEM delta values are observed to consistently increase as fluid volume increased. The greatest change in the rate of SEM deltas is observed between no induced tissue fluid and 1 mL tissue fluid injection breaching the clinical threshold of SEM A > 0.6. SEM delta values are statistically significantly different from baseline after f ml of fluid injection (p<0.001), with a mean increase in SEM delta of 0.637 [95% CI 0.32,0.95], The mean increase between injections decreases as fluid volume increased, with increases of 0.278 [95% CI -0.04,0.6], 0.136 [95% CI -0.18, 0.45] and 0.034 [95% CI -0.28, 0.35] after 2 ml, 3 ml and 4 ml respectively. The clinical threshold of 0.6 is breached after 1 ml injection. The rate of change of SEM deltas slows as the tissue is increasingly saturated, to a point where at 4mL the change in SEM deltas flattens out, representing the upper limit of the dielectric constant of the induced fluid. Furthermore, although the volume of fluid injected increased in subsequent injections (up to 4 mL), the depth of injection and the tissue cross-section for measurements of SEM remain unchanged over time, possibly resulting in the induced edema expanding longitudinally, thereby contributing to measurements trending towards a saturation curve.EXAMPLE 7 : Data Analysis and Statistics[00911 Data analysis and Statistics for Examples 1-6 are performed as follows. Absolute SEM values and SEM delta values are recorded in an excel spreadsheet (Microsoft Excel, Microsoft, Washington, United States) and analyzed in a Jupyter computational notebook (Project Jupyter, United States) using pandas and statsmodels Python packages. Analyses between control sites and injection sites for each level of fluid injection are performed using ANOVA, with Tukey's Honest Significant Difference test for multiple comparisons, with a family -wise error rate of p<0.05. Ordinary least-squares linear regression is used to analyze the effect of distance from injection site on SEM scan sensitivity. Analyses of SEM delta scores vs fluid injections are performed using ANOVA, with Tukey’s Honest Significant Difference test for multiple comparisons, with a family-wise error rate of p<0.05.[00921 From the foregoing, it will be appreciated that the present invention can be embodied in various ways, which include but are not limited to the following:10093] Embodiment 1 : A method of treating an increase in fluid content in tissue in a patient in need thereof, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (d) determining in the patient in need thereof that the volume of fluid is greater at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold; and (e) administering a treatment for localized edema. |(H194] Embodiment 2: The method according to embodiment 1, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

[0095] Embodiment 3: The method according to embodiment 1, wherein the first location and the second location are spaced no less than 10 cm apart.

[0096] Embodiment 4: The method according to embodiment 1, wherein the predetermined threshold is 0.6.

[0097] Embodiment 5: A method of determining the relative volume of fluid in tissue, the steps comprising: (a) taking tw o or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (d) determiningthat the relative volume of fluid is at least 1 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6.

[0098] Embodiment 6: The method according to embodiment 5, further comprising the step of determining that the volume of fluid is at least 2ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.9.

[0099] Embodiment 7 : The method according to embodiment 5, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

[0100] Embodiment 8: The method according to embodiment 5, wherein the first location and the second location are spaced no less than 10 cm apart.

[0101] Embodiment 9: The method according to embodiment 5, wherein the predetermined threshold is 0.6.

[0102] Embodiment 10: A method of measuring an increase in the volume of fluid in tissue, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at a first location on the body; (b) taking two or more SEM readings at a second location on the body; (c) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (d) determining that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.|0103] Embodiment 11 : The method according to embodiment 10, wherein the tw o or more SEM readings taken at the first location are spaced no more than 4 cm apart.

[0104] Embodiment 12: The method according to embodiment 10, wherein the first location and the second location are spaced no less than 10 cm apart.

[0105] Embodiment 13: The method according to embodiment 10, wherein the predetermined threshold is 0.6.

[0106] Embodiment 14: A method of determining the efficacy of a treatment at a first location of the body with localized edema, the steps comprising: (a) taking two or more subepidermal moisture (SEM) readings at the first location on the body with localized edema; (b) taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema; (c) calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (d) administering the treatment; (e) taking two or more SEM readings at the first location post-treatment; (1) taking two or more SEM readings at thesecond location post-treatment; (g) calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location posttreatment and the second location post-treatment; (h) determining that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and (i) determining that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.

[0107] Embodiment 15: The method according to embodiment 14, wherein the two or more SEM readings taken at the first location are spaced no more than 4 10 cm apart.

[0108] Embodiment 16: The method according to embodiment 14, wherein the first location and the second location are spaced no less than 10 cm apart.[01091 Embodiment 17: The method according to embodiment 14, wherein the treatment is systemic.

[0110] Embodiment 18: The method according to embodiment 14, wherein the treatment is localized.

[0111] Embodiment 19: The method according to embodiment 14, wherein the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low- friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress.

[0112] Embodiment 20: A method of adjusting a treatment for localized edema, the steps comprising: (a) administering a level-N treatment for localized edema; (b) taking two or more subepidermal moisture (SEM) readings at a first location on the body with localized edema; (c) taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema; (d) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; € continuing to administer the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold; (f) administering a level-(N+l) treatment if the SEM delta is greater than the firstpre-determined threshold; and (g) administering a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.[0113 j Embodiment 21 : The method according to embodiment 20, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

[0114] Embodiment 22: The method according to embodiment 20, wherein the first location and the second location are spaced no less than 10 cm apart.

[0115] Embodiment 23 : The method according to embodiment 20, wherein the treatment is systemic.

[0116] Embodiment 24: The method according to embodiment 20, wherein the treatment is localized.[0117| Embodiment 25 : The method according to embodiment 20, wherein the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low- friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad. repositioning the patient with a wedge, and changing to a dynamic mattress.[0118 Embodiment 26: A system for use in treating increase in fluid content in tissue in a patient in need thereof, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient's body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; and (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (ii) determining in the patient in need thereof that the SEM delta is greater than or equal to a predetermined threshold; (iii) determining in the patient in need thereof that the fluid content is greater at the location where the highest SEM reading is taken; and (iv) providing a notification that the patient is in need of treatment.[0119[ Embodiment 27: A system for measuring an increase in localized edema, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and asecond location on the patient’s body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; and (c) a non-transitory computer- readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and (ii) providing a signal that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.[0120! Embodiment 28: A system for determining the efficacy of a treatment at a first location of the body with localized edema, comprising: (a) an SEM scanner configured to (i) take two or more SEM readings at a first location and a second location on the patient’s body prior to treatment, and to (ii) take two or more SEM readings at the first location and the second location on the patient’s body post-treatment; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner (i) the four or more SEM readings at the first location and the second location prior to treatment, and (ii) the four or more SEM readings at the first location and the second location post-treatment; and (c) a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location prior to treatment;(ii) calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location post-treatment;(iii) providing a signal that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and (iv) providing a signal that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.

[0121] Embodiment 29: A system for adjusting the level of treatment in a patient receiving a level-N treatment for localized edema, comprising: (a) an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; (b) a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the secondlocation; (c) a non-transi lory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: (i) calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; (ii) providing a signal to a caregiver to continue administering the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold; (iii) providing a signal to a caregiver to administer a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold; and (iv) providing a signal to a caregiver to administer a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.

[0122] While the invention has been described with reference to particular aspects, it will be understood by those skilled in the art that various changes may be made and equivalents maybe substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to a particular situation or material to the teachings of the invention without departing from the scope of the invention. Therefore, it is intended that the invention not be limited to the particular aspects disclosed but that the invention will include all aspects falling within the scope and spirit of the appended claims.

Claims

CLAIMSWe claim:

1. A method of treating an increase in fluid content in tissue in a patient in need thereof, the steps comprising: a. taking two or more subepidermal moisture (SEM) readings at a first location on the body; b. taking two or more SEM readings at a second location on the body; c. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; d. determining in the patient in need thereof that the volume of fluid is greater at the location where the highest SEM reading is taken and that the SEM delta is greater than or equal to a predetermined threshold; and e. administering a treatment for localized edema.

2. The method of claim 1 , wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

3. The method of claim 1, wherein the first location and the second location are spaced no less than 10 cm apart.

4. The method of claim 1, wherein the predetermined threshold is 0.6.

5. A method of determining the relative volume of fluid in tissue, the steps comprising: a. taking two or more subepidermal moisture (SEM) readings at a first location on the body; b. taking two or more SEM readings at a second location on the body; c. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and d. determining that the relative volume of fluid is at least 1 ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.6.

6. The method of claim 5, further comprising the step of determining that the volume of fluid is at least 2ml greater at the location with the highest SEM reading if the SEM delta is greater than 0.9.

7. The method of claim 5, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

8. The method of claim 5, wherein the first location and the second location are spaced no less than 10 cm apart.

9. The method of claim 5, wherein the predetermined threshold is 0.6.

10. A method of measuring an increase in the volume of fluid in tissue, the steps comprising: a. taking two or more subepidermal moisture (SEM) readings at a first location on the body; b. taking two or more SEM readings at a second location on the body; c. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and d. determining that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.

11. The method of claim 10, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

12. The method of claim 10, wherein the first location and the second location are spaced no less than 10 cm apart.

13. The method of claim 10, wherein the predetermined threshold is 0.6.

14. A method of determining the efficacy of a treatment at a first location of the body with localized edema, the steps comprising: a. taking two or more subepidermal moisture (SEM) readings at the first location on the body with localized edema; b. taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema; c. calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; d. administering the treatment; e. taking two or more SEM readings at the first location post-treatment; f. taking two or more SEM readings at the second location post-treatment;g. calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location posttreatment and the second location post-treatment; h. determining that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacy threshold; and i. determining that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.

15. The method of claim 14, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

16. The method of claim 14, wherein the first location and the second location are spaced no less than 10 cm apart.

17. The method of claim 14, wherein the treatment is systemic.

18. The method of claim 14, wherein the treatment is localized.

19. The method of claim 14, wherein the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low-friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress.

20. A method of adjusting a treatment for localized edema, the steps comprising: a. administering a level-N treatment for localized edema; b. taking two or more subepidermal moisture (SEM) readings at a first location on the body with localized edema; c. taking two or more SEM readings at a second location on the body, wherein the second location of the body does not have localized edema; d. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; e. continuing to administer the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, whereinthe first pre-determined threshold is higher than the second pre-determined threshold; f. administering a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold; and g. administering a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.

21. The method of claim 20, wherein the two or more SEM readings taken at the first location are spaced no more than 4 cm apart.

22. The method of claim 20, wherein the first location and the second location are spaced no less than 10 cm apart.

23. The method of claim 20, wherein the treatment is systemic.

24. The method of claim 20, wherein the treatment is localized.

25. The method of claim 20, wherein the treatment is selected from the group consisting essentially of providing good nutrition, providing a standard mattress, turning the patient at regular intervals, providing a heel boot, changing the support surface, applying dressing to the patient’s skin, changing the sheet cover to a low-friction sheet over, providing a low-friction padded mattress surface, turning the patient at shorter intervals, applying a barrier cream to the patient’s skin, applying neuromuscular stimulation, applying topical cream to enhance perfusion, providing a silicone pad, repositioning the patient with a wedge, and changing to a dynamic mattress.

26. A system for use in treating increase in fluid content in tissue in a patient in need thereof, comprising: a. an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; b. a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; and c. a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of:i. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; ii. determining in the patient in need thereof that the SEM delta is greater than or equal to a predetermined threshold; iii. determining in the patient in need thereof that the fluid content is greater at the location where the highest SEM reading is taken; and iv. providing a notification that the patient is in need of treatment.

27. A system for measuring an increase in localized edema, comprising: a. an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; b. a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location: and c. a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: i. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; and ii. providing a signal that the volume of fluid is increased at the location where the highest SEM reading is taken relative to the location where the lowest SEM reading is taken if the SEM delta is greater than or equal to a predetermined threshold.

28. A system for determining the efficacy of a treatment at a first location of the body with localized edema, comprising: a. an SEM scanner configured to (i) take two or more SEM readings at a first location and a second location on the patient’s body prior to treatment, and to (ii) take two or more SEM readings at the first location and the second location on the patient’s body post-treatment; b. a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner (i) the four or more SEM readings at the first location and the second location prior to treatment, and (ii)the four or more SEM readings at the first location and the second location post-treatment; and c. a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: i. calculating a first SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location prior to treatment; ii. calculating a second SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location post-treatment; iii. providing a signal that the treatment is efficacious if the second SEM delta is lower than the first SEM delta by a predetermined efficacythreshold; and iv. providing a signal that the treatment is not efficacious if the second SEM delta is not lower than the first SEM delta by a predetermined efficacy threshold.

29. A system for adjusting the level of treatment in a patient receiving a level-N treatment for localized edema, comprising: a. an SEM scanner configured to take two or more SEM readings at a first location and a second location on the patient’s body; b. a processor electronically coupled to the SEM scanner, the processor configured to receive from the SEM scanner the four or more SEM readings at the first location and the second location; c. a non-transitory computer-readable medium electronically coupled to the processor and contains instructions that, when executed on the processor, perform the steps of: i. calculating an SEM delta between the highest and the lowest SEM reading from the four or more SEM readings taken at the first location and the second location; ii. providing a signal to a caregiver to continue administenng the level-N treatment if the SEM delta is between a first pre-determined threshold and a second pre-determined threshold, wherein the first pre-determined threshold is higher than the second pre-determined threshold;providing a signal to a caregiver to administer a level-(N+l) treatment if the SEM delta is greater than the first pre-determined threshold; andproviding a signal to a caregiver to administer a level-(N-l) treatment if the SEM delta is lesser than the second pre-determined threshold.

Citation Information

Patent Citations

  • SEM Trend Analysis

    US20190175098A1

  • Strategic Treatment of Pressure Ulcer Using Sub-Epidermal Moisture Values

    US20200069240A1

  • Methods of treating deep and early-stage pressure induced tissue damage

    US20220240840A1

  • ViewUS20190175098A1onEspacenetopensinnewtab

  • ViewUS20200069240A1onEspacenetopensinnewtab